Anlon Healthcare Limited has announced the price band for its initial public offering at ₹86-91 per equity share, with the subscription period scheduled to open on August 26, 2025, and close on August 29, 2025. The pharmaceutical intermediates and active pharmaceutical ingredients (APIs) manufacturer aims to raise approximately ₹121 crore through this public offering.
IPO Structure and Timeline
The IPO consists entirely of a fresh issue of 1.33 crore shares with a face value of ₹10 each. The floor price and cap price represent 8.6 times and 9.1 times the face value of the equity shares, respectively. The lot size has been set at 164 equity shares, requiring a minimum investment of ₹14,104 for retail investors.
The allocation structure reserves at least 75% of shares for qualified institutional buyers (QIBs), with not more than 15% allocated to non-institutional investors (NIIs) and not more than 10% reserved for retail investors. The basis of allotment is expected to be finalized on September 1, 2025, with listing scheduled for September 3, 2025, on both BSE and NSE.
Company Profile and Market Position
Founded in 2013, Anlon Healthcare Limited operates as a chemical manufacturing company specializing in the production of highly pure pharmaceutical intermediates for API production. The company also manufactures active pharmaceutical ingredients used in various formulations for medicines, nutraceuticals, personal care products, and animal health applications.
The company competes with established players including Kronox Lab Sciences, AMI Organics, and Supriya Lifescience in the pharmaceutical intermediates and APIs market.
Financial Performance
Anlon Healthcare has demonstrated strong financial growth, with revenue increasing by 81% and profit after tax rising by 112% during the fiscal year ended March 31, 2025, compared to the previous fiscal year. The company reported a profit of ₹9.65 crore for fiscal year 2024, up from ₹5.82 crore in the previous year, despite revenue declining from ₹112.9 crore to ₹66.6 crore during that period.
For the ten-month period ending January 2025, the company achieved a profit of ₹12 crore with revenue of ₹77.2 crore, indicating continued business momentum.
Use of Proceeds
The funds raised through the IPO will be allocated across several strategic initiatives. The company plans to invest ₹30.7 crore in expanding its manufacturing plant capacity, while ₹43.15 crore will support working capital requirements. Additional proceeds will be used for full or partial repayment of outstanding secured borrowings and general corporate purposes.
Risk Factors
The company has identified key operational risks in its regulatory filings, noting that it is subject to strict technical specifications, quality requirements, and regular inspections and audits by customers or their representatives. Failure to comply with prescribed quality standards and technical specifications could result in loss of business, cancellation of existing and future orders, and potential warranty claims, which could negatively impact business operations and financial condition.
Market Infrastructure
Interactive Financial Services Ltd. serves as the exclusive book-running lead manager for the offering, while Kfin Technologies Ltd. acts as the registrar for the issue. The anchor investor allocation is scheduled for August 25, 2025, one day before the public subscription opens.
